This content is from: Features

What’s behind the drug patent furore in South Africa

South Africa’s draft IP policy has generated a lot of negative publicity. But, as David Cochrane explains, further consultation is hoped for and any amendments to the Patent Act are some way off

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial